Adjustable Minus-Lens Mouse Model for Human-Like Myopia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mouse models do not accurately replicate the symptoms of human excessive myopia, such as eye axis length, refractive index, and sclera thickness, making them incomplete as myopia models, and there is a lack of effective treatments for myopia.
Innovation Solution
A mouse myopia-induced model is developed using a minus lens and an adjustment mechanism, combined with endoplasmic reticulum stress suppressants and inhibitors, to replicate human myopia symptoms and facilitate therapeutic agent screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional myopia models use chick, tree shrew, or guinea pig, then the model can be used for myopia research, but gene manipulation is difficult and genetic element research is limited
Solution Approach 1:
The patent uses mouse as a model organism that can be easily genetically manipulated and whose myopia development can be induced to copy human myopia conditions. The mouse model replicates the key features of human axial myopia while being amenable to genetic modification techniques, thus solving the contradiction between model accuracy and ease of genetic manipulation.
2Productivity
If mouse myopia models use a minus lens, then myopia can be induced, but the model does not accurately replicate human excessive myopia symptoms such as eye axis length, refractive index, and sclera thickness
Solution Approach 1:
The patent employs multiple intervention methods including minus lens wearing, ocular expansion agents, and scleral cross-linking to simultaneously modify multiple parameters (eye axis length, refractive index, sclera thickness) to accurately replicate human excessive myopia symptoms, thus resolving the contradiction between preparation efficiency and symptom replication accuracy.
3Loss of information
If conventional myopia models are used, then research can be conducted, but effective treatment for suppressing myopia is not established
Solution Approach 1:
The patent utilizes the mouse model to screen for compounds that can suppress myopia progression by monitoring changes in eye axis length and refractive error, providing feedback on treatment effectiveness. This systematic approach to drug screening and validation establishes a reliable pathway from molecular mechanism understanding to effective treatment development.
Data Source
AI summary
A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.